A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
Stopped Study terminated.24 subjects enrolled;provided adequate data for decision making.
Conditions
Interventions
- DRUG: 5.0g SRT501
- DRUG: Bortezomib
Sponsor
Sirtris, a GSK Company
Collaborators